Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
celiac disease
Biotech
Barinthus lays off 25%, sidelines prostate cancer program
Barinthus used positive data from a pair of phase 2 trials for its hepatitis B therapy as justification for jettisoning a quarter of its workforce.
James Waldron
Jun 13, 2024 5:30am
Equillium swaps subcutaneous cytokine inhibitor for oral option
Dec 21, 2023 10:58am
Takeda taps Innate to develop celiac antibody-drug conjugates
Apr 3, 2023 5:08am
GSK drops celiac disease program acquired in Sitari buyout
Feb 1, 2023 6:40am
9 Meters' celiac drug doesn't measure up in phase 3
Jun 21, 2022 2:13pm
Forte's top shareholder calls on the company to liquidate
May 25, 2022 11:29am